Key Points
- Director Elisabeth Bjork sold 10,000 Pharvaris shares on May 20 at an average price of $29.32, for total proceeds of $293,200. After the sale, she still held 15,167 shares, a nearly 40% reduction in her position.
- Pharvaris reported a smaller-than-expected quarterly loss, posting EPS of -$0.70 versus the consensus estimate of -$0.82. Analysts currently expect the company to lose $3.25 per share for the full year.
- Wall Street remains broadly positive on PHVS despite some mixed calls, with 10 Buy ratings, 2 Hold ratings, and 1 Sell rating. The consensus rating is "Moderate Buy" with an average target price of $49.18, well above the recent trading price near $29.68.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Elisabeth Bjork sold 10,000 shares of the business's stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $29.32, for a total value of $293,200.00. Following the transaction, the director directly owned 15,167 shares of the company's stock, valued at approximately $444,696.44. The trade was a 39.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Pharvaris Price Performance
Pharvaris stock opened at $29.68 on Friday. The business has a 50 day moving average of $28.46 and a 200-day moving average of $26.81. Pharvaris N.V. has a 1 year low of $15.46 and a 1 year high of $33.33. The company has a market capitalization of $1.94 billion, a P/E ratio of -9.33 and a beta of -2.34.
Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. Equities analysts anticipate that Pharvaris N.V. will post -3.25 EPS for the current year.
Analyst Ratings Changes
PHVS has been the subject of several recent research reports. Royal Bank Of Canada lowered their price objective on Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a research note on Monday, April 6th. Wolfe Research initiated coverage on Pharvaris in a research note on Thursday, April 9th. They issued an "outperform" rating and a $42.00 price objective for the company. Wedbush upped their price objective on Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a research note on Tuesday, April 7th. Wall Street Zen raised Pharvaris from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a research note on Tuesday, April 21st. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $49.18.
Read Our Latest Report on Pharvaris
Institutional Trading of Pharvaris
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL acquired a new stake in Pharvaris during the 3rd quarter valued at approximately $1,943,000. Patient Square Capital LP increased its position in Pharvaris by 41.4% during the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company's stock valued at $8,617,000 after purchasing an additional 101,098 shares during the period. JPMorgan Chase & Co. increased its position in Pharvaris by 710.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company's stock valued at $676,000 after purchasing an additional 23,743 shares during the period. Integral Health Asset Management LLC acquired a new stake in Pharvaris during the 3rd quarter valued at approximately $4,990,000. Finally, Boothbay Fund Management LLC increased its position in Pharvaris by 735.1% during the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company's stock valued at $3,373,000 after purchasing an additional 118,994 shares during the period.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
